BIO.DE Biotest AG on XETRA pre-market: €42.20 shows oversold bounce opportunity
BIO.DE stock trades at €42.20 in XETRA pre-market and looks set for an oversold bounce setup after a modest pullback. We see low volume of 175 shares early today and a year range of €40.40–€43.20, which frames a tight trading band. As an AI-powered market analysis platform, Meyka AI flags this as a short-term mean-reversion trade for traders watching liquidity and catalysts in Germany’s biotechnology sector.
BIO.DE stock pre-market snapshot
Price is €42.20 on XETRA pre-market, down 0.94% from the previous close of €42.60. Volume is light at 175 shares versus an average volume of 129, giving a relative volume of 1.36. The intraday range opened at €42.20 with a high of €43.00 and a low of €42.20.
Why this is an oversold bounce setup for BIO.DE stock
Recent small pullback leaves the share price close to the 200-day average of €41.71, while the 50-day average sits at €42.54, creating a mean-reversion range. Low turnover and a tight year range increase the odds of a short-term bounce if buyers re-enter around current levels. Traders should watch for confirmation: a volume pick-up above 200 shares and a close above €43.00.
BIO.DE stock fundamentals and valuation
Biotest AG reports EPS of -0.63 and a PE ratio of -66.98, reflecting recent losses. Price-to-sales is 2.92 and price-to-book is 3.22, while the current ratio is 4.93, indicating solid short-term liquidity. Debt-to-equity is 1.31, so leverage is above sector norms and adds risk to any recovery thesis.
Meyka AI rates BIO.DE with a score out of 100
Meyka AI rates BIO.DE with a score out of 100: 66.84 | Grade B | Suggestion: HOLD. This grade factors in S&P 500 and sector comparisons, financial growth, key metrics, forecasts, and analyst consensus. These grades are informational only and are not financial advice.
Technicals, trade plan and price triggers for BIO.DE stock
Short-term technicals point to bounce risk near moving averages: price sits between the 50-day (€42.54) and 200-day (€41.71) lines. On a bounce, initial resistance is €43.20 (year high) and first support is €40.40 (year low). A conservative trade plan: enter partial positions on a confirmed close above €42.80 with a stop at €40.80 and a first target at €44.00.
Risks, catalysts and market context for BIO.DE stock
Key risk items include negative EPS, below-average cash flow, and a company rating of D+ from recent data. Major catalyst dates include the next earnings announcement on 2025-11-10. Sector performance in Healthcare in Germany shows modest YTD strength; any broader biotech weakness could push BIO.DE lower. For related market references see Investing.com competitor comparison and Investing.com ADR note.
Final Thoughts
Short-term traders can treat BIO.DE stock as an oversold bounce candidate on XETRA at €42.20, given the tight trading range and proximity to both the 50-day (€42.54) and 200-day (€41.71) averages. Meyka AI’s forecast model projects a one-year target of €42.05, implying a modest downside of -0.34% versus today’s price. Use clear entry rules: wait for a volume-confirmed move above €42.80 or a protective stop under €40.80. Remember the company posts negative EPS (-0.63) and carries leverage (debt-to-equity 1.31), so risk management matters. Forecasts are model-based projections and not guarantees. For more live updates visit our Biotest page at Biotest BIO.DE on Meyka.
FAQs
Is BIO.DE stock a buy right now?
We view BIO.DE stock as a short-term bounce trade, not a long-term buy. Meyka AI gives a B grade and suggests HOLD. Watch for volume above 200 shares and price action above €42.80 before scaling in.
What are the main risks for BIO.DE stock?
Major risks include negative EPS (-0.63), tight free cash flow, and higher leverage with debt-to-equity 1.31. Sector shocks in biotech or weak earnings can push shares below €40.40.
What price targets should traders use for BIO.DE stock?
A tactical target for an oversold bounce is €44.00. Meyka AI’s one-year model projects €42.05, implying small downside. Use stops near €40.80 for defined risk.
How does company data affect the BIO.DE stock outlook?
Biotest’s liquidity ratios and current ratio 4.93 support near-term stability, but negative margins and cash-flow metrics weigh on the outlook. Monitor earnings and inventory days at 500.13 for operational risk signals.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
